Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma

NCT05694416 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT05694416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05694416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
Lead sponsor
Zhongnan Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2023
Completion date
March 1, 2025
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mgmt-unmethylated glioblastoma